Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Business Wire
? Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV? SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025 LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights.“The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV,” said Craig Tooman, President and Chief Executive Officer at Silence. “The SANRECO Phase 2 trial of divesiran in PV patients continues to progress towards full enrollment this year and remains our top priority.”Rhonda Hellums, Silence’s Chief Financial Officer, said, “We are continuing to prioritize investments in key are
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- With 35% ownership, Silence Therapeutics plc (NASDAQ:SLN) insiders have a lot at stake [Yahoo! Finance]Yahoo! Finance
- TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
- TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of GrowthBusiness Wire
- Silence Therapeutics CEO Craig Tooman steps down [Seeking Alpha]Seeking Alpha
- Silence Therapeutics Announces Leadership Changes [Yahoo! Finance]Yahoo! Finance
SLN
Sec Filings
- 12/23/25 - Form 8-K
- 12/22/25 - Form 4
- 12/22/25 - Form 4
- SLN's page on the SEC website